You are here: Industry Insights > Humira

News List

AbbVie loses bid to hoard documents in Humira patent fight with Boehringer fiercepharma
February 24, 2019
Boehringer Ingelheim is one of the only—if not the only—biosimilar makers still challenging AbbVie’s Humira patents in court. And the German drugmaker just won a skirmish in that high-stakes battle, gaining access to documents AbbVie had fought to keep se
Humira Topped for Seven Times in Sales and Remaining Global Drug King PharmaSources/1℃
February 13, 2019
The 2018 sales of Humira reached USD19.936 billion, securing its position as the global drug king and topping for seven times in terms of sales!
Global Humira sales near $20bn, but expect decline in 2019 bioprocessintl
February 03, 2019
Looking to 2019, AbbVie says US sales of its bestseller monoclonal antibody Humira (adalimumab) will continue to grow but expects a $2 billion hit from biosimilar competition.
Humira biosimilars catch fire in Europe and could take half the market in a year fiercepharma
January 28, 2019
AbbVie investors have been bracing for the mother of all patent cliffs—the loss of exclusivity on the company’s $18-billion-per-year Humira—and now its impact is starting to come into view.
Trump’s war on drug pricing looks set to continue pharmaphorum
January 04, 2019
Shrugging off warnings from president Donald Trump, pharma companies have announced US price hikes on more than 250 prescription drugs for 2019....
Lilly's Taltz beats out AbbVie's megadrug Humira in psoriatic arthritis showdown fiercepharma
December 19, 2018
What’s a surefire way to get noticed in any field? Beat out a behemoth. And that’s what Eli Lilly’s Taltz has just done in psoriatic arthritis (PsA).
FDA approves biosimilar of blockbuster Humira pharmaphorum
December 17, 2018
A Humira biosimilar, produced by drug maker Sandoz, has been given the green light from the US Food and Drug Administration (FDA)......
AbbVie suffers fresh setback with lung cancer drug Rova-T pharmaphorum
December 10, 2018
AbbVie has suffered a further setback with its oncology drug Rova-T, after early data from a lung cancer trial suggested that patients were living longer when treated with standard therapy.
Boehringer Ingelheim axes biosimilars development outside US pharmaphorum
December 06, 2018
Boehringer Ingelheim has said it has axed development of its biosimilars outside Europe, focusing instead on getting its Humira near-copy on the US market as soon as possible.
Pfizer secures Humira licence agreements with AbbVie pharmaceutical-technology
December 04, 2018
Pfizer has resolved licensing issues regarding its adalimumab biosimilar that was deemed too close to AbbVie’s Humira (adalimumab).....

Previous page 1 2 3 4 5 6 7 Next page